<DOC>
	<DOC>NCT00047476</DOC>
	<brief_summary>To evaluate the efficacy of dexmethylphenidate (d-MPH) in the treatment of chemotherapy-related fatigue in adult cancer subjects.</brief_summary>
	<brief_title>D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Dexmethylphenidate Hydrochloride</mesh_term>
	<criteria>Diagnosis of cancer, excluding primary or metastatic brain tumors. Treated with a minimum of four cycles of a cytotoxic chemotherapy, the last chemotherapy treatment must have been completed at least 2 months prior to study entry. Physical/neurological examination consistent with the absence of a focal neurological deficit Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intrauterine device; barrier contraceptive with spermicide; or vasectomized partner). Subjects must be able to adhere to the protocol requirements. Subjects must understand and voluntarily sign an informed consent document. Subjects must be a native English speaker or fluent in English, and have at least an eighth grade education.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2004</verification_date>
	<keyword>neurobehavioral function</keyword>
	<keyword>chemobrain</keyword>
	<keyword>chemo brain</keyword>
	<keyword>fatigue</keyword>
	<keyword>memory loss</keyword>
	<keyword>exhausted</keyword>
	<keyword>trouble concentrating</keyword>
</DOC>